Hormonal
GLP-1 receptor agonists (GLP-1RAs) and dual/triple incretin agonists produce clinically relevant hepatic improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), including MASH resolution, liver fat reduction, and prevention of fibrosis worsening.
If you have MASH or MASLD, especially with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a valuable treatment option. They not only help with weight and blood sugar but also directly improve liver health by reducing fat and inflammation. While lifestyle changes remain important, these medications can help achieve the necessary weight loss (7-10%) if you struggle to do so alone. Discuss these options with your gastroenterologist.
In Phase I – III trials, GLP-1RAs are associated with clinically relevant hepatic improvements including MASH resolution, liver fat reduction, and preventing worsening fibrosis.
Why this rating
Based on a narrative review of Phase I-III clinical trials and systematic reviews.
Source
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri et al. · Expert Opinion on Investigational Drugs · 2025
DOI 10.1080/13543784.2025.2473062
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →